When was Vir Biotechnology founded?

Vir Biotechnology was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Vir Biotechnology located?

Vir Biotechnology is headquartered in San Francisco, United States. It is registered at San Francisco, California.

Who is the current CEO of Vir Biotechnology?

George Scangos of Vir Biotechnology.

How many employees does Vir Biotechnology have?

As of Jun 30, 2026, the latest employee count at Vir Biotechnology is 472.

Is Vir Biotechnology a funded company?

Vir Biotechnology is a funded company, having raised a total of $216M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Sep 26, 2017.

When was the latest funding round of Vir Biotechnology?

Vir Biotechnology's latest funding was a $***** Post IPO round on May 06, 2020, with participation from 0 investor.

What is the annual revenue of Vir Biotechnology?

Annual revenue of Vir Biotechnology is between $50M and $100M as on Dec 31, 2025

Where does Vir Biotechnology rank among its competitors?

Vir Biotechnology ranks 174th amongst 2756 active competitors, of which 919 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Vir Biotechnology?

Vir Biotechnology's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Vir Biotechnology - 2026 Company Profile, Team, Funding, Competitors & Financials

Vir Biotechnology is a public company based in San Francisco (United States), founded in 2017 by Klaus Frueh. It operates as a Developer of therapeutics for the treatment of infectious diseases. Vir Biotechnology has raised $216M in funding from Gates and Arch Venture Partners. The company has 2756 active competitors, including 919 funded and 674 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of therapeutics for the treatment of infectious diseases. The company's approach is focused on immune programming to manipulate pathogen-host interactions. The company has developed drugs for Covid-19, HBV, HIV, and influenza-A.

Website: www.vir.bio/
Social
Registered Address: San Francisco, California

Key Metrics

Founded Year

2017

Location

San Francisco, United States

Stage

Public

Total Funding

$216M in 4 rounds

Latest Funding Round

Post IPO, May 06, 2020, $*****

Investors

Gates & 13 more

Ranked

174^th among 2756 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

472 as on Jun 30, 2026

Investment & Acquisitions

Agenovir & 1 more

Similar Companies

Moderna & 525 more

Exit Details

Public

View Vir Biotechnology's full profile

Vir Biotechnology is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Vir Biotechnology International GmbH CIN: 1554170 , Switzerland, Deadpooled	May 27, 2024	-	-	-
Vir Biotechnology, Inc. CIN: 812730369 , United States, Active	Dec 31, 2016	$50M - $100M (As on Dec 31, 2025)	370 (As on Dec 31, 2024)	-

Vir Biotechnology got listed on Oct 11, 2019.

Click here to take a look at Vir Biotechnology's IPO in detail

Vir Biotechnology has raised a total funding of $216M over 4 rounds. Its first funding round was on Sep 26, 2017. Vir Biotechnology has 14 institutional investors.

Here is the list of recent funding rounds of Vir Biotechnology:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 06, 2020	4248510	Post IPO	7620104	9099363	7037836	6303630
Apr 29, 2020	3356165	Post IPO	8698465	4244725	3582629	GSK
Jun 29, 2018	1639838	Series A	9735216	2132835	7671910	4260431

Access funding benchmarks and valuations. Sign up today!

View details of Vir Biotechnology's funding rounds and investors

The founders of Vir Biotechnology is Klaus Frueh. George Scangos is the CEO of Vir Biotechnology.

Here are the details of Vir Biotechnology's key team members:

Klaus Frueh: Co-Founder of Vir Biotechnology.
Contact Info: 1 email address
George Scangos: CEO of Vir Biotechnology.

View details of Vir Biotechnology's Founder profiles and Board Members

Vir Biotechnology's employee count trend

Vir Biotechnology has 472 employees as of Jun 26. Here is Vir Biotechnology's employee count trend over the years:

Employee count trend for Vir Biotechnology

Uncover Vir Biotechnology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vir Biotechnology include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Vir Biotechnology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
7th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
174th	Vir Biotechnology 2017, San Francisco (United States), Public	Developer of therapeutics for the treatment of infectious diseases	$216M	Google Ventures, SoftBank Vision Fund & 12 others	59/100